SEC Filing Summary: PerkinElmer, Inc. (Form 10-Q)
Business Context and Reporting Period
This filing is a Quarterly Report on Form 10-Q for PerkinElmer, Inc. (Note: The request metadata lists "REVVITY, INC.", but the filing text explicitly identifies the registrant as PerkinElmer, Inc.). The report covers the quarterly period ended March 30, 2003. The company operates through four reporting segments: Life Sciences, Analytical Instruments, Optoelectronics, and Fluid Sciences. During the fourth quarter of 2002, the company combined its Life Sciences and Analytical Instruments units into a new business unit named "Life and Analytical Sciences."
Key Financial Metrics
| Metric | Q1 2003 (Unaudited) | Q1 2002 (Unaudited) |
|---|---|---|
| Sales | $358.4 million | $346.3 million |
| Operating Income | $19.3 million | ($14.9 million) Loss |
| Net Income (Loss) | $2.4 million | ($147.4 million) Loss |
| Diluted EPS | $0.02 | ($1.18) |
| Cash from Operating Activities | $24.1 million | ($31.1 million) Used |
| Total Debt (Short + Long Term) | $760.3 million | $805.5 million |
| Cash and Cash Equivalents | $129.8 million | $130.6 million |
| Cash Held in Escrow | $154.5 million | $186.5 million |
Note: Q1 2002 Net Loss included a $117.8 million after-tax charge related to the adoption of SFAS No. 142 (Goodwill impairment).
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 4% year-over-year, driven by growth in digital imaging, sensors, environmental applications, and genetic screening, partially offset by declines in pharmaceutical R&D and aerospace markets.
- Profitability Turnaround: The company returned to operating profitability ($19.3M) compared to a loss of $14.9M in the prior year. This improvement was aided by a $17.0 million inventory adjustment taken in Q1 2002 and significant cost reductions.
- Expense Reduction: Selling, general, and administrative (SG&A) expenses decreased 14% to $92.9 million, primarily due to headcount reductions and cost controls. R&D expenses decreased 4% to $20.9 million.
- Restructuring: The company recorded a net benefit of $0.4 million from restructuring charges in Q1 2003, compared to $9.2 million in charges in Q1 2002.
- Discontinued Operations: Loss from discontinued operations improved significantly to $0.96 million in Q1 2003 from $8.9 million in Q1 2002, following the shutdown of the Telecommunications Component business and the sale of the Entertainment Lighting business.
Guidance, Outlook, and Risks
- Cost Savings Targets: Management targets annualized pre-tax cost savings of $30.0 million to $45.0 million from the Life and Analytical Sciences integration beginning in 2004, with interim savings of $12.0 million to $25.0 million in 2003.
- Debt Obligations: The company is required to redeem all remaining zero coupon convertible debentures (approx. $155 million accreted value) in August 2003. Approximately $155 million is currently held in escrow for this purpose.
- Market Risks: The company faces risks from cyclical downturns in key industries (pharmaceutical, biomedical, semiconductor, aerospace), foreign exchange rate fluctuations (64% of sales are international), and the need to introduce new products to avoid obsolescence.
- Legal and Environmental: The company is subject to various legal proceedings, including a class action lawsuit regarding misleading statements, and environmental remediation obligations with an accrued liability of $7.0 million.
Investor Verification Checklist
- Verify the status of the $155 million escrow account intended for the August 2003 redemption of zero coupon convertible debentures.
- Monitor the progress of the Life and Analytical Sciences integration to ensure projected cost savings ($12M-$25M in 2003) are realized.
- Assess the impact of continued weakness in pharmaceutical R&D and aerospace markets on the Life Sciences and Fluid Sciences segments.
- Review the company's compliance with financial covenants in its senior credit facility and 8 7/8% Notes, particularly regarding leverage and interest coverage ratios.
- Track the resolution of the class action lawsuit and potential environmental liabilities beyond the current $7.0 million accrual.